Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$----
P/E Ratio
--
P/B Ratio
--
Industry P/E
--
Debt to Equity
--
ROE
--
ROCE
--
Div. Yield
--
Book Value
--
EPS
--
CFO
$-77.42 Mln
EBITDA
$-97.36 Mln
Net Profit
$-101.86 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
BioCardia Inc. Warrant (BCDAW)
| -51.20 | -51.97 | -69.50 | -98.43 | -84.39 | -- | -- |
|
BSE Sensex*
| 1.23 | 1.57 | 3.97 | 7.26 | 11.47 | 20.39 | 11.18 |
|
2023
|
|
|---|---|
|
BioCardia Inc. Warrant (BCDAW)
| -98.49 |
|
BSE Sensex
| 18.74 |
|
BSE Sensex
| 18.74 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell... therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California. Read more
CEO, President & Director
Dr. Peter A. Altman Ph.D.
CEO, President & Director
Dr. Peter A. Altman Ph.D.
Headquarters
Sunnyvale, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of BioCardia Inc Warrant (BCDAW) is $0.01 (NASDAQ) as of 02-Aug-2024 16:00 EDT. BioCardia Inc Warrant (BCDAW) has given a return of -84.39% in the last 3 years.
BioCardia Inc Warrant (BCDAW) has a market capitalisation of -- as on 13-Aug-2024. As per Value Research classification, it is a company.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the BioCardia Inc Warrant (BCDAW) and enter the required number of quantities and click on buy to purchase the shares of BioCardia Inc Warrant (BCDAW).
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.
The CEO & director of Dr. Peter A. Altman Ph.D.. is BioCardia Inc Warrant (BCDAW), and CFO & Sr. VP is Dr. Peter A. Altman Ph.D..
There is no promoter pledging in BioCardia Inc Warrant (BCDAW).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|
| BioCardia Inc. Warrant (BCDAW) | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of BioCardia Inc Warrant (BCDAW) was $0 Mln.
$0.00
(
